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Early in the coronavirus disease 2019 (COVID-19) pandemic, the
Centers for Disease Control and Prevention (CDC) published
return-to-work criteria for healthcare personnel who had
recovered from severe acute respiratory coronavirus virus 2
(SARS-CoV-2) infection. These criteria were most recently
updated on April 3, 2020.1 The CDC has endorsed 2 different
approaches to allow staff to return to work: a symptom or
time-based strategy and a test-based strategy. Many institutions
initially adopted the test-based strategy, in part because CDC
initially recommended it as the preferred option (but no longer
does so) and, in part, because it seemed the more definitive or
conservative of the 2 CDC options.
As a result of using the test-based strategy, many institutions
now have significant numbers of staff whose nasopharyngeal swabs
remain RT-PCR positive for COVID-19, despite the fact that they
have recovered from their episodes of illnesses and have been
asymptomatic for weeks or, in some instances, months. These staff
effectively remain in limbo; they feel well but have persistently
positive PCR studies, and driven by the test-based strategy, they
cannot return to the workplace until they have 2 negative
COVID-19 PCR tests.
This phenomenon (persistently positive PCR tests for extended
periods after recovery from COVID-19 infection) has now been
well described in the literature, including a paper describing the
first 12 COVID-19 cases in the United States,2 a detailed study
of 9 cases from Germany3 and a recent paper from Manitoba.4
Similarly, Strong and Feldmann described a lack of clear linkage
between PCR positivity and viral infectiousness during the
Ebola epidemic.5 The Center for Infectious Diseases of the
National Academy of Medicine of Singapore issued a position
statement, including data demonstrating that, of 73 COVID-19
patients, virus was not cultivable in any of them after day 11 of their
illnesses.6 Similarly, the Korean Centers for Disease Control
evaluated 285 patients who were found to be PCR positive for
COVID-19 8–82 days following recovery from a documented
COVID-19 illness.7 They were able to attempt viral culture in
108 of these individuals and could not isolate virus from any of
them.7 Each of the COVID-19 studies cited here performed viral
culture in addition to PCR testing for viral RNA. In each of the
studies, coronavirus RNA could be detected long after virus could
no longer be cultured from upper respiratory samples. These
data document that individuals who had illnesses not requiring
hospitalization, who recovered from the disease and who remain
persistently positive by PCR, no longer harbor cultivable virus
10 days after symptom onset. Notably, these studies have assessed
relatively healthy populations who developed COVID-19 infection
but were not severely ill. We do not yet know whether the 10-day
cutoff is appropriate for immunocompromised healthcare person-
nel (HCP) who develop COVID-19, but it clearly does not apply
for HCP who suffered severe disease (eg, with hospitalization
and/or prolonged intubation).8,9 Such individuals will have to be
managed on a case-by-case basis until more data become available.
In the Canadian study cited above, the authors retrospectively
evaluated 90 previously identified positive samples by both PCR
and viral culture in Vero-cells. They compared both the number
of days from onset of symptoms to the day the test was performed
as well as the cycle thresholds of PCR positivity to recovery of
viable virus in tissue culture.4 In no instance were the investigators
able to recover virus if >8 days had elapsed from the onset of
symptoms, despite the persistence of positive PCR tests. In
addition, if the cycle threshold for the sample was >24, they could
not recover virus in tissue culture.4
Relying on a cycle threshold limit as a return-to-work criterion
has some limitations. Cycle thresholds are not directly comparable
from site to site or even from test to test. In addition to the number
of copies of RNA in a given sample, cycle thresholds depend on a
variety of factors, including the specific gene target(s) and the
number of gene targets chosen for the assay, the platform used,
variability in reagents used from site to site, and more.
Optimally, to use the cycle threshold, an institution would validate
the procedure in its own laboratory, demonstrating, as the study
from Manitoba did, that samples above a certain cycle threshold
did not contain cultivable virus. The challenge in doing such
a validation is that you need a Biosafety Level 3 laboratory to do
the tissue culture work, and many, if not most centers will not have
access to those resources. Additionally, if any aspects of the PCR
assay change, revalidation is appropriate. Another challenge in
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using cycle thresholds is that not all diagnostic nucleic acid
amplification assays use RT-PCR, so cycle thresholds are not
available, and some rapid instruments use PCR but do not yield
cycle threshold values. Finally, regarding the standardization of
testing, if the clinical laboratory community developed universal
standards for SARS-CoV-2 similar to the World Health
Organization’s standards for hepatitis B and C, a multicenter study
of all currently manufactured SARS-CoV-2 nucleic acid amplifica-
tion tests could be designed to correlate the cycle threshold values
on each platform for patients who have positive and negative viral
cultures. Clinical laboratories could then calibrate their assays
using the universal standard, thus allowing laboratories to estimate
virus viability from the cycle threshold with some certainty. To
assure proficiency and reliability, the College of American
Pathologists could develop proficiency panels for labs for quality
assurance. This standardization scenario represents a desired
future state; for the time being, we will have to rely on other
strategies.
Conversely, relying on time from symptom development as a
return-to-work criterion is also fraught with a few challenges.
The onset of COVID-19 may be insidious and may be difficult
for an individual provider to pin down. Recall bias may affect
the provider’s ability to be precise about the onset of symptoms.
As asymptomatic provider surveillance testing expands, protocols
will have to be developed to manage asymptomatically infected
individuals.
So how do we approach these issues, balancing the safety of
patients and staff with the need to avoid having staff unnecessarily
sidelined staff who could be contributing to an important
pandemic response when we need them the most? Given the data
cited here, the test-based strategy appears likely to delay HCP
return to work longer than is necessary for the protection of
patients and coworkers around them, especially at a time when
most facilities are recommending universal masking of HCP.
For HCP who had relatively mildly symptomatic cases (ie, man-
aged as an outpatient), a symptom-based strategy as recommended
by the CDC appears appropriate based on the same data. For
asymptomatic cases, questions remain about relative transmission
risk and possibly about timing of infection related to testing. The
CDC strategy of returning those HCP to work 10 days after their
positive test seems reasonable. Staff who developed more severe
COVID-19 infections (eg, those requiring hospitalization and/or
critical care support) may represent a special case; as such, severely
ill patients may shed virus for longer periods from symptom
onset.8,9 In addition to the requirement that at least 10 days have
passed since symptoms first appeared, the CDC guidelines also
requires that at least 72 hours have passed since recovery, defined
in their guidance as resolution of fever and improvement in
respiratory symptoms.1 Adding the qualifier that “respiratory
symptoms must have improved” to the “10 days from symptom
onset” requirement may help address this issue. Additional,
unanswered questions remain about how to manage immunocom-
promised HCP. Fewer data are available on viral viability duration
in this latter population, and the need for further research on this
topic is urgent.
Thus, based on these data, one approach to managing recovered
HCP who work primarily with patient populations at high risk of
complications would be to use the “time from symptom
development” strategy plus “sustained improvement in respiratory
symptoms” and add a safety factor (eg, adding an additional week
or 2) to the time from symptom onset, or perhaps adding 2 weeks
from test positivity for asymptomatic staff detected as positive.
Institutions can decide howmuch of a cushion is appropriate, based
on local factors, patient populations, etc. In addition, the use of
source-control masking should be required for such individuals.
The dynamic nature of the pandemic necessitates that the
healthcare epidemiology community continue to closely monitor
the data as it emerges and to adjust policies and procedures, both
to maximize patient and staff safety, while preserving the labor
force that is essential to our ultimate success.
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*After this manuscript was submitted and accepted, the Centers for Disease
Control and Prevention modified their recommended “return to work” criteria
to state that a test-based strategy is no longer recommended and to advocate
strategies basically consistent with the suggestions outlined in this paper (See
https://www.cdc.gov/coronavirus/2019-ncov/hcp/return-to-work.html).
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